Evidence map›Paper›PMID 41714802›Full record

ArticleScientific reports2026

Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy.

Kathrin Hessling, Caroline Brand, Christian Schwöppe, Mirjam Gerwing, Stefanie Pavelka, Andrew F Berdel, Heike Hintelmann, Rainer Hamacher, Carsten Müller-Tidow, Gerlinde Egerer and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Kathrin Hessling *Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert‑Schweitzer‑Campus 1, 48149, Muenster, Germany.
Caroline Brand *Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert‑Schweitzer‑Campus 1, 48149, Muenster, Germany.
Christian Schwöppe *Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert‑Schweitzer‑Campus 1, 48149, Muenster, Germany.
Mirjam GerwingDepartment of Radiology, University Hospital Muenster, Muenster, Germany.
Stefanie PavelkaDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert‑Schweitzer‑Campus 1, 48149, Muenster, Germany.
Andrew F BerdelDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert‑Schweitzer‑Campus 1, 48149, Muenster, Germany.
Heike HintelmannDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert‑Schweitzer‑Campus 1, 48149, Muenster, Germany.
Rainer HamacherDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
Carsten Müller-TidowCenter for Internal Medicine 5, University Hospital Heidelberg, Heidelberg, Germany.
Gerlinde EgererCenter for Internal Medicine 5, University Hospital Heidelberg, Heidelberg, Germany.
Wolfgang HartmannGerhard-Domagk-Institute for Pathology, University Hospital Muenster, Muenster, Germany.
Inga GrünewaldGerhard-Domagk-Institute for Pathology, University Hospital Muenster, Muenster, Germany.
Lars H LindnerSarKUM, Department of Medicine III, Ludwig Maximilians University Hospital Großhadern, Munich, Germany.
Dorit Di GioiaSarKUM, Department of Medicine III, Ludwig Maximilians University Hospital Großhadern, Munich, Germany.
Judith S HeckerDepartment of Medicine III, School of Medicine and Health and TranslaTUM Center for Translational Cancer Research, Technische Universitaet Muenchen, Munich, Germany.
Sabine MaurerDepartment of Medicine III, School of Medicine and Health and TranslaTUM Center for Translational Cancer Research, Technische Universitaet Muenchen, Munich, Germany.
Daniel PinkDepartment of Oncology and Palliative Care, HELIOS Klinikum Bad Saarow, Bad Saarow, Germany.
Marius FriedUniversity Cancer Center Mainz (UCT Mainz) and Clinic and Polyclinic for Internal Medicine III, University Hospital Mainz, Mainz, Germany.
Sergio A Zapata BonillaUniversity Cancer Center Mainz (UCT Mainz) and Clinic and Polyclinic for Internal Medicine III, University Hospital Mainz, Mainz, Germany.
Anne-Marie ScheubleDepartment of Medicine (Oncology, Gastroenterology, Hepatology, Pulmonology), University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany (CCCG), Leipzig, Germany.
Florian LordickDepartment of Medicine (Oncology, Gastroenterology, Hepatology, Pulmonology), University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany (CCCG), Leipzig, Germany.
Philipp IvanyiDepartment of Hematology and Oncology, Medizinische Hochschule Hannover, Hannover, Germany.
Manfred FobkerCentral Laboratory, University Hospital Muenster, Muenster, Germany.
Georg LenzDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert‑Schweitzer‑Campus 1, 48149, Muenster, Germany.
Joachim GerssInstitute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
Torsten Kessler *Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert‑Schweitzer‑Campus 1, 48149, Muenster, Germany.
Wolfgang E Berdel *Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert‑Schweitzer‑Campus 1, 48149, Muenster, Germany. berdel@uni-muenster.de.
Christoph Schliemann *Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert‑Schweitzer‑Campus 1, 48149, Muenster, Germany. Christoph.Schliemann@ukmuenster.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trabectedin is standard for r/r soft tissue sarcomas. tTF-NGR accumulates in tumor vasculature leading to tumor vascular occlusion and tumor infarction. Both compounds in sequence could trap trabectedin inside tumors and increase its efficacy, which then optimizes the pro-coagulatory activity of tTF-NGR. This report summarizes translational data and results of the safety run-in patient cohort of the TRABTRAP trial combining trabectedin plus tTF-NGR. A dose of trabectedin of 1.5 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsSarcomaThromboplastinTrabectedinAdultAgedAntineoplastic Agents, AlkylatingCarbolinesFemaleHeterocyclic Compounds, 4 or More RingsHumansMaleMaximum Tolerated DoseMiddle AgedNeoplasm Recurrence, LocalTreatment OutcomeAntineoplastic Agents, AlkylatingCarbolinesHeterocyclic Compounds, 4 or More RingsPM 01183ThromboplastinTrabectedinCD13-targeted tissue factor tTF-NGRSoft tissue sarcomasTrabectedin

Identifiers

PMID41714802
PMCPMC12923852

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.